Proteome Sciences PLC 2023 AR2
The report outlines Proteome Sciences plc's financial and operational performance for the year ended December 31, 2023. Despite a challenging macroeconomic environment that led to a 35% decrease in group revenues to £5.03m and an operating loss of £1.62m, the company continued strategic investments in its Frankfurt and San Diego laboratories. Key developments included the launch of single-cell proteomics in October 2023 and the expansion of its Tandem Mass Tag product portfolio. The company also established a new US laboratory in San Diego to better serve its primary market and participate in US government grants.
Company: Proteome Sciences PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 89
Back to company
Proteome Sciences PLC
Report And Financial Statements
The report outlines Proteome Sciences plc's financial and operational performance for the year ended December 31, 2023. Despite a challenging macroeconomic environment that led to a 35% decrease in group revenues to £5.03m and an operating loss of £1.62m, the company continued strategic investments in its Frankfurt and San Diego laboratories. Key developments included the launch of single-cell proteomics in October 2023 and the expansion of its Tandem Mass Tag product portfolio. The company also established a new US laboratory in San Diego to better serve its primary market and participate in US government grants.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees